A Study Of PF-04449913 Administered Alone In Select Solid Tumors

Pfizer

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Drug: PF-04449913

Study type: Interventional

Funder types: Industry

Identifiers

NCT01286467

B1371002

Details and patient eligibility

About

This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.

Enrollment: 23 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological or cytological diagnosis of advanced/metastatic solid tumor
• Adequate Bone Marrow Function
• Adequate Renal Function
• Adequate Liver Function

Exclusion criteria

• Patients with known symptomatic brain metastases requiring steroids
• Current active treatment on another clinical trial
• Major surgery or radiation therapy within 4-weeks of starting study treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

23 participants in 1 patient group

1

Experimental group

Treatment:

Drug: PF-04449913